Why the study?
ECMO poses unique thrombotic and hemorrhagic risks, and the optimal anticoagulant choice is unknown.
Does bivalirudin reduce circuit-related thrombosis and mortality compared to heparin in adult patients receiving ECMO?
Does bivalirudin reduce circuit-related thrombosis and mortality compared to heparin in adult patients receiving ECMO?
In adult ECMO patients, bivalirudin may be associated with fewer circuit-related thrombotic events and improved survival compared to heparin, without increasing bleeding risk.
No takes yet. Share an insight, caveat, or question.
Bivalirudin was associated with fewer thrombotic events and lower mortality than heparin in adult ECMO; leaves open confirmation by randomized trials.
Wieruszewski et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: